[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Indonesia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":709},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,185,0,25,[9,49,82,107,134,159,187,215,256,279,317,342,360,383,411,444,471,496,540,560,584,607,635,659,685],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635623","a-study-of-multiple-micronutrient-supplementation-mms-to-increase-adherence-with-digital-technology-100635623",false,"NCT07555093","A Study of Multiple Micronutrient Supplementation (MMS) to Increase Adherence With Digital Technology","A Randomized Controlled Trial in Lombok: Assessing Factors Influencing Acceptance and Adherence to Multiple Micronutrient Supplementation (MMS) Using Digital Tools","SMART-MMS","Inclusion Criteria:\n\n* Pregnant women up to 32 weeks\n* Pregnant women stay in the site at least during the study period\n\nExclusion Criteria:\n\n* Lost to follow up\n* Moving to another area\n* Death\n* Abortus\n* Stillbirth",true,"FEMALE","14 Years",{"count":22,"type":23},10012,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this randomized clinical trial is to learn whether a digital health intervention can improve adherence to Multiple Micronutrient Supplementation (MMS) among pregnant women in Lombok Island. The study also aims to understand how individual characteristics, socio-economic factors, maternal health status, and antenatal care services influence adherence to MMS.\n\nThe main questions it aims to answer are:\n\n1. Does a digitally supported intervention increase adherence to MMS compared to standard care?\n2. Does the type of MMS packaging (bottle vs. blister) affect adherence?\n3. In the second stage, does adding calcium supplementation affect adherence to MMS?\n\nResearchers will compare four groups to see if digital support and packaging type improve MMS adherence:\n\n1. Standard care with MMS in bottles\n2. Standard care with MMS in blister packs\n3. Digital intervention with MMS in bottles\n4. Digital intervention with MMS in blister packs\n\nApproximately 10,012 pregnant women will be randomly assigned to one of these four groups using a 2×2 factorial design.\n\nParticipants will:\n\n1. Receive MMS through either bottle or blister packaging\n2. Receive either standard care or a digital health intervention (such as reminders or digital support tools)\n3. Attend routine antenatal care services\n4. Be followed throughout pregnancy, delivery, and up to 42 days after childbirth\n\nIn the second stage of the study, participants from community health posts (Posyandu) will also receive calcium supplementation in addition to MMS. Additional 900 pregnant women will be enrolled from the same Puskesmas areas participating in the MMS study to evaluate the addition of calcium supplementation. These participants will be recruited outside of the main MMS cohort and will be equally distributed across the four study arms. This stage aims to assess whether adding calcium supplementation influences adherence to MMS among pregnant women.\n\nParticipants will be monitored during pregnancy, at delivery, and during the postnatal care period up to 42 days after birth.\n\nThis study represents an early implementation of Multiple Micronutrient Supplementation (MMS) in Lombok Island, where MMS is not yet routinely available through government programs. Only selected primary healthcare centers (Puskesmas) that are randomized into the study will provide MMS to eligible participants. While the government has begun introducing MMS in other areas, it has not yet been implemented in Lombok.\n\nThe digital health intervention will only be provided to pregnant women who agree to participate in the study and provide informed consent. All participants will continue to receive standard antenatal care (ANC) services in accordance with existing government programs.\n\nThis study is also integrated with the ongoing distribution of iron and folic acid supplementation (TTD) in Lombok. Pregnant women who do not consent to participate in the study or do not receive MMS will continue to receive TTD as part of routine care outside of the study.",[29,30],"Pregnancy","Adherence",[32,29,33,34,35],"MMS","Digitalization","adherence","Antenatal Care","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":40},"2026-06-13",{"date":44,"type":23},"2027-06",{"name":46,"class":47},"Summit Institute for Development, Indonesia","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100598310","study-of-clinical-and-patient-reported-outcomes-in-adults-with-moderate-to-severe-copd-treated-with-breztritrixeo-100598310","NCT07069829","Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri\u002FTrixeo","Real-world, International, Multicentre, Non-interventional, Prospective Cohort to Assess Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri\u002FTrixeo in Routine Care Settings","iCHOROS","Inclusion Criteria:\n\nThe study will include patients who were prescribed BGF, but not yet initiated, according to the label (SmPC) and local market reimbursement criteria. Patients will only be included in the study if they meet the following inclusion criteria:\n\n1. Patients diagnosed with COPD, at least 12 months before baseline, as assessed per physician's routine practice or as documented in the patient's chart.\n2. Male or female patients aged over 30 years and under 80 years at the time of enrolment.\n3. Patients providing a written Informed Consent\\* prior to inclusion to the study.\n\n   \\*Prescription of BGF should be prior to the signed informed consent and the decision to prescribe this therapy is clearly separated from the physician's decision to include the patient in the current study.\n4. Patients able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will not be eligible to participate in the study:\n\n1. Patients with COPD due to documented α-1 antitrypsin deficiency.\n2. Patients with recent (≤3 months) major cardiac or pulmonary events that required hospitalization (e.g., myocardial infarction, pulmonary embolism).\n3. Patients previously treated with triple fixed-dose combination therapies 12 months before the screening visit or treated with Multiple Inhaled Triple Therapy (MITT) within the last 3 months before the screening visit.\n4. Patients hospitalized due to COPD exacerbations within the last 30 days prior to enrolment.\n5. Currently pregnant (or intending to become pregnant), breastfeeding, or lactating women.\n6. Patients with a current diagnosis of asthma, active tuberculosis, lung cancer or lung metastasis, significant bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases, or other active clinically significant pulmonary diseases.\n7. Patients currently participating in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study or participation in any interventional trial in the last 30 days prior to enrolment.\n8. Patients with respiratory tract infection (including COVID-19 infection) ) that has not resolved ≤30 days prior to BGF MDI initiation and those exhibiting persistent long-COVID symptoms are excluded from the study.","ALL","30 Years","80 Years",{"count":61,"type":23},1400,"OBSERVATIONAL","Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI\u002FTRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life.\n\nThe iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \\& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations",[65],"Chronic Obstructive Pulmonary Disease",[67,68,69,70],"COPD","Moderate to Severe Chronic Obstructive Pulmonary Disease","Severe Exacerbations","BGF - Budesonide\u002FGlycopyrrolate\u002FFormoterol Fumarate","2026-06-26",{"date":73,"type":40},"2026-06-29",{"date":75,"type":40},"2025-12-15",{"date":77,"type":23},"2027-09-30",{"name":79,"class":80},"AstraZeneca","INDUSTRY",36,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100645120","a-theory-based-fluid-self-management-program-100645120","NCT07677605","A Theory-based Fluid Self-management Program","Effects of Self-Management Program on Interdialytic Weight Gain Control in Hemodialysis Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Receiving maintenance hemodialysis for ≥ 3 months\n* Undergoing hemodialysis two times per week on a regular schedule\n* Possession of a smartphone with active WhatsApp use\n* Ability to read and understand Indonesian, with support provided in Javanese where necessary.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment or diagnosed psychiatric disorders affecting comprehension or participation, as documented in the medical record.\n* Severe visual, hearing, or communication impairments not corrected by assistive devices\n* Current hospitalisation or unstable medical condition\n* Planned kidney transplantation or dialysis modality change during the study period\n* Participation in another interventional study related to fluid management or self-management\n* Inability to engage with the WhatsApp Channel follow-up","18 Years",{"count":91,"type":23},160,[26],"This study aims to evaluate the efficacy of an intervention guided by the IFSMT, in which structured education and digitally delivered reinforcement strategies are designed to enhance self-management processes, including knowledge and beliefs, self-regulation skills, and social facilitation, among patients undergoing maintenance hemodialysis. The intervention, delivered via a mobile platform three times daily over two months, seeks to improve fluid control adherence and hemodialysis self-management behaviours, and to reduce interdialytic weight gain and stabilise pre-hemodialysis mean arterial pressure, compared with standard education alone.",[95],"Hemodialysis Patient",[97,98],"Fluid-Self Management Program","Interdialytic Weight Gain Control","NOT_YET_RECRUITING","2026-06-24",{"date":39,"type":40},{"date":39,"type":23},{"date":104,"type":23},"2027-02-28",{"name":106,"class":47},"National Taipei University of Nursing and Health Sciences",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":57,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100585909","the-decision-cto-extended-10-y-follow-up-100585909","NCT06908499","The DECISION-CTO Extended 10 Y Follow-up","Ten-Year Outcomes of Randomized Comparison of Drug-eluting Stent Implantation Versus Optimal Medical Treatment in Patient With Chronic Total Occlusion: DECISION-CTO Trial","DecisionCTO10Y","Inclusion Criteria:\n\n1. Clinical 1) Patients with angina or silent ischemia and documented ischemia 2) Patients who are eligible for intracoronary stenting 3) Age \\>18 years\n2. Angiographic 1) De novo lesion Chronic Total Occlusion (CTO) 2) Reference vessel size ≥ 2.5 mm by visual estimation 3) At least one CTO lesions located in proximal or mid epicardial coronary artery.\n\n   (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery)\n3. CTO definition: TIMI (Thrombolysis in Myocardial Infarction) flow 0 or 1 with estimated duration over 3 months\n\n   * The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome, or\n   * In patients without a history of acute coronary syndrome, from the first episode of effort angina consistent with the location of the occlusion\n\n     1. Angiographically defined total occlusion over 3 months\n     2. If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)\n\nExclusion Criteria:\n\n1. History of bleeding diathesis or coagulopathy\n2. Pregnant state\n3. Three vessel CTOs\n4. Known hypersensitivity or contra-indication to contrast agent and heparin\n5. ST-elevation acute myocardial infarction requiring primary stenting\n6. Culprit total occlusion presented with acute coronary syndrome suggesting acute or recent occlusion\n7. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels 4) Distal epicardial coronary artery CTO lesions 5) Two vessel proximal segment CTOs\n8. Hematological disease (Neutropenia \\\u003C3000\u002Fmm3, Thrombocytopenia \\\u003C100,000\u002Fmm3)\n9. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal\n10. Renal dysfunction, creatinine ≥ 2.0mg\u002FdL\n11. Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent\n12. Left ventricular ejection fraction \\\u003C30%\n13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.\n14. Non-cardiac co-morbid conditions are present with limited life expectancy or that may result in protocol non-compliance (per site investigator's medical judgment).","19 Years",{"count":117,"type":23},840,"The goal of this clinical trial is to compare long term efficacy of drug-eluting stent implantation compare to optimal medical treatment in patient with chronic total occlusion in a very long-term follow-up (minimum 10 years) period.",[120],"Coronary Artery Disease",[122,123,124],"Chronic Total Occlusion","Drug-eluting Stent Implantation","Optimal Medical Treatment","2026-06-23",{"date":100,"type":40},{"date":128,"type":40},"2026-04-01",{"date":130,"type":23},"2026-12-31",{"name":132,"class":47},"Seung-Jung Park",19,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":18,"sex":57,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100593980","phase-3-a-study-to-evaluate-v181-dengue-vaccine-in-healthy-participants-2-to-17-years-of-age-v181-005mobilize-1-100593980","NCT07013487","A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005\u002FMOBILIZE-1)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age","The key Inclusion Criteria include but are not limited to:\n\n* Is generally healthy based on medical history and physical examination.\n\nThe key Exclusion Criteria include but are not limited to:\n\n* Has a known or suspected impairment of immunological function.\n* Has a history of congenital or acquired immunodeficiency.\n* Has a documented human immunodeficiency virus (HIV) infection or is breastfeeding from a mother with documented HIV infection.\n* Has a documented history of hepatitis B or C infection.\n* Has a bleeding disorder contraindicating subcutaneous vaccination or repeated venipuncture.\n* Has a serious or progressive disease, including but not limited to cancer, uncontrolled diabetes, severe cardiac, renal or hepatic insufficiency, or systemic autoimmune or neurologic disorders.\n* Has a known neurologic or cognitive behavioral disorder, including encephalitis\u002Fmyelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders.\n* Previous receipt of a dengue vaccine or plans to receive any dengue vaccine (investigational or approved) for the duration of the study (other than the study vaccine).\n* Received systemic corticosteroids \\\u003C30 days before receipt of study intervention or is expected to require systemic corticosteroids ≤28 days after receipt of study intervention.\n* Has received a blood transfusion or blood products, including immunoglobulins, ≤6 months before receipt of study intervention or plans to receive a blood transfusion or blood products (including immunoglobulins) ≤28 days after receipt of study intervention.\n* Has received immunosuppressive therapies, including chemotherapeutic agents used to treat cancer or other conditions, treatments associated with organ or bone marrow transplantation, or autoimmune disease, ≤6 months before receipt of study intervention or plans to receive immunosuppressive therapies ≤28 days after receipt of study intervention.","2 Years","17 Years",{"count":144,"type":23},12000,[146],"PHASE3","The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.",[149],"Healthy","2026-06-19",{"date":125,"type":40},{"date":153,"type":40},"2025-06-11",{"date":155,"type":23},"2031-10-24",{"name":157,"class":80},"Merck Sharp & Dohme LLC",41,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":62,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100075056","pompe-disease-registry-protocol-100075056","NCT00231400","Pompe Disease Registry Protocol","Pompe Disease Registry","Inclusion Criteria:\n\nAll patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and\u002For documentation of 2 GAA gene mutations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria in this Registry",{"count":167,"type":23},2000,"5 Years","The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development\u002Freimbursement, and for other research and non-research related purposes.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Pompe disease population.\n* To evaluate the long-term effectiveness of alglucosidase alfa.",[171,172],"Glycogen Storage Disease Type II","Pompe Disease",[174,175,172,176,177,178],"Glycogen Storage Disease Type II (GSD-II)","GSD-II","Pompe Disease (late-onset)","Acid Maltase Deficiency Disease","Glycogenosis II",{"date":125,"type":40},{"date":181,"type":40},"2004-09-15",{"date":183,"type":23},"2034-01-31",{"name":185,"class":80},"Genzyme, a Sanofi Company",272,{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":62,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":214},"100072469","fabry-disease-registry--pregnancy-sub-registry-100072469","NCT00196742","Fabry Disease Registry & Pregnancy Sub-registry","Fabry Disease Registry Protocol","Inclusion Criteria\n\n* Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL (alpha-galactosidase) enzyme activity and\u002For mutation(s) in the gene coding for αGAL.\n* Fabry Pregnancy Sub-registry:\n\n  * Eligible women must:\n\n    * be enrolled in the Fabry Registry.\n    * be pregnant, or have been pregnant with appropriate medical documentation available.\n    * provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nExclusion Criteria Fabry Registry: There are no exclusion criteria. Fabry Pregnancy Sub-registry: There are no exclusion criteria.",{"count":195,"type":23},9000,"52 Weeks","The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.\n\nThe primary objectives of the Registry are:\n\n* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;\n* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;\n* To characterize and describe the Fabry population as a whole;\n* To evaluate the long-term safety and effectiveness of Fabrazyme®\n\nFabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development\u002Freimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.",[199],"Fabry Disease",[201,202,203,204,205,206,207,208],"alpha Galactosidase A","aGAL (alpha-galactosidase)","Fabry","GL3 (globotriaosylceramide)","Anderson-Fabry Disease","angiokeratomas","GLA deficiency (gene deficiency)","errors in metabolism",{"date":125,"type":40},{"date":211,"type":40},"2001-07-31",{"date":183,"type":23},{"name":185,"class":80},284,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":18,"sex":223,"minAge":115,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":227,"briefSummary":228,"conditions":229,"keywords":235,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":254,"locationsCount":48},"100644079","effect-of-cordyceps-supplementation-timing-on-physiological-responses-and-aerobic-adaptation-in-athletes-100644079","NCT07664345","Effect of Cordyceps Supplementation Timing on Physiological Responses and Aerobic Adaptation in Athletes","Optimization of Athlete Recovery: Effects of Cordyceps Supplementation Timing on Inflammatory Response, Oxidative Stress, Muscle Damage, and Aerobic Adaptation Following Acute and Chronic Exercise Training","CORD-RECOV","Inclusion Criteria:\n\n* Male or female participants aged 19-21 years.\n* Students enrolled in the Sport Coaching Education Program (Pendidikan Kepelatihan Olahraga).\n* Apparently healthy and free from known cardiovascular, metabolic, respiratory, neuromuscular, or musculoskeletal disorders that could affect participation in exercise training.\n* Regularly participate in physical exercise at least three times per week during the previous three months.\n* Willing to comply with all study procedures, exercise protocols, supplementation schedules, and assessment sessions.\n* Provide written informed consent before participation.\n\nExclusion Criteria:\n\n* Current injury or musculoskeletal condition that limits participation in exercise training.\n* History of cardiovascular disease, uncontrolled hypertension, diabetes mellitus, respiratory disease, or other medical conditions that may increase exercise-related risk.\n* Use of antioxidant supplements, herbal supplements, ergogenic aids, or anti-inflammatory medications within four weeks prior to study enrollment.\n* Known allergy or hypersensitivity to Cordyceps or any component of the study supplements.\n* Smoking or excessive alcohol consumption during the study period.\n* Failure to comply with supplementation or exercise protocols.\n* Participation in another research study during the study period.\n* Participants presenting acute infection, fever, or inflammatory conditions within two weeks prior to baseline assessment.","MALE","21 Years",{"count":226,"type":23},30,[26],"Athletes frequently perform high-intensity exercise to improve physical performance and aerobic capacity. However, such training can induce exercise-induced muscle damage, oxidative stress, and inflammatory responses that may delay recovery and compromise subsequent training adaptations. Optimizing recovery strategies is therefore essential to maintain performance, reduce injury risk, and support long-term athletic development.\n\nCordyceps is a medicinal mushroom that contains several bioactive compounds, including cordycepin and polysaccharides, which have demonstrated antioxidant, anti-inflammatory, and immunomodulatory properties. Although previous studies have reported beneficial effects of Cordyceps supplementation on exercise performance and physiological function, limited evidence exists regarding the optimal timing of supplementation relative to exercise.\n\nThis study aims to investigate the effects of different Cordyceps supplementation timing strategies on physiological responses and aerobic adaptation following acute and chronic exercise training. Participants will be assigned to receive Cordyceps supplementation before exercise, after exercise, or placebo. The study will evaluate biomarkers of inflammation (IL-6), oxidative stress (MDA), muscle damage (CK), aerobic capacity (VO2max), and neuromuscular performance assessed using countermovement jump (CMJ) testing.\n\nThe findings of this study are expected to provide evidence-based recommendations regarding nutritional recovery strategies and supplementation timing to optimize recovery and training adaptation in athletes and physically active individuals.",[230,231,232,233,234],"Exercise Recovery","Exercise-induced Muscle Damage","Oxidative Stress","Sports Performance","Aerobic Capacity",[236,237,238,230,239,240,232,241,242,243,244,245,246,247,248],"Cordyceps","Cordyceps Supplementation","Supplement Timing","Athletic Performance","Sports Nutrition","Inflammation","Creatine Kinase","Interleukin-6","Malondialdehyde","VO2max","Countermovement Jump","VALD ForceDecks","Exercise Adaptation","2026-06-17",{"date":100,"type":40},{"date":39,"type":23},{"date":253,"type":23},"2026-09-15",{"name":255,"class":47},"Surabaya State University",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":57,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":278},"100633913","a-real-world-study-to-investigate-cardiovascular-risk-profile-among-newly-diagnosed-type-2-diabetes-mellitus-t2dm-participants-100633913","NCT07532863","A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants","A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia","CRISTALSEA","Inclusion Criteria:\n\n* Aged greater than equal to (≥) 40 and less than (\\\u003C) 70 years\n* Male or female\n* Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023\n\nExclusion Criteria:\n\n* If any exclusion criterion is met, the participant will be excluded from the study.\n* T1DM or gestational diabetes\n* Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM\n* Pregnant women\n* With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease\n* Died within 12 months after first diagnosis of T2DM\n* Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM","40 Years","70 Years",{"count":267,"type":23},400,"The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.",[270],"Diabetes Mellitus, Type 2",{"date":272,"type":40},"2026-06-18",{"date":274,"type":40},"2026-03-13",{"date":39,"type":23},{"name":277,"class":80},"Novo Nordisk A\u002FS",6,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":18,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":48},"100642220","evaluation-of-the-effectiveness-of-the-genomics--science-dojo-30-learning-method-in-improving-research-skills-and-scientific-writing-among-researchers-in-indonesia-100642220","NCT07607301","Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Method in Improving Research Skills and Scientific Writing Among Researchers in Indonesia","Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Method in Improving Research Skills and Scientific Writing Among Researchers in Indonesia: A Randomized Controlled Trial","DOJO","Inclusion Criteria:\n\n* Registered participants of Genomics \\& Science DOJO 3.0\n* Teams consisting of two members\n* Submission of research concept note\n* Completion of screening and assessment stages (administratively and substantially through blind concept note screening and team's curriculum vitae)\n* Willingness and commitment to participate in the full program will be ensured through a structured confirmation process.\n* In addition, participants will be required to review, sign, and submit a commitment letter outlining the full schedule, expectations for attendance, and participation requirements.\n* Information regarding program schedule and participation expectations will be communicated at multiple stages, including during registration, program launch, and post-selection, to ensure participants are fully informed prior to confirming their participation.\n* Involvement\u002F attendance of the first author\n\nExclusion Criteria:\n\n* Incomplete registration or documentation\n* Failure to meet team composition requirements\n* Withdrawal before intervention\n* Incomplete baseline data",{"count":288,"type":23},96,[26],"The goal of this study is to rigorously evaluate the effectiveness of the DOJO 3.0 learning methodology in enhancing research skills and scientific writing among researchers in Indonesia compared to non-DOJO learning method. The main questions it aims to answer are:\n\nHow effective is the Dojo 3.0 methodology in improving participants' research skills and scientific writing, including critical thinking, data analysis ability, knowledge acquisition, and scientific manuscript quality and publication progress? How do participants' experiences, perceptions of the learning process and teaching quality, as well as their engagement, performance, and learning behaviors, differ between the intervention (DOJO) and control groups throughout the program?\n\nResearchers will compare two groups, control group and intervention group to see if there is a significant difference between these two groups.\n\nStandard learning method Non-DOJO (Control) DOJO learning method (Intervention)\n\nFor the intervention group, participants will participate in Shinjitsu class, an interactive dynamic lecture with real time engagement, an offline minicamp session with lecture that is more intense, intentionally more provocative and dynamic, wounded healer, shinjitsu ninja obstacles, shinjitsu ninja run, sparring and Tournament.",[292,293,294,295,296,297,298,299,300,301],"Workshop","Critical Thinking Skill","Data Analysis Skill","Personal Empowerment","Manuscript Quality","Genomics","Science","Research Publication","Learning Methodology","Quality of Teaching",[303,304,305,306,307,308],"Learning Method","Research Skill","Scientific Writing","Critical Thinking","Randomized Controlled Trial","Genomics and Science","2026-06-12",{"date":311,"type":40},"2026-06-15",{"date":313,"type":40},"2026-06-04",{"date":315,"type":23},"2027-03",{"name":46,"class":47},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":18,"sex":57,"minAge":89,"maxAge":264,"enrollmentInfo":324,"targetDuration":4,"studyType":24,"phases":326,"briefSummary":322,"conditions":328,"keywords":331,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":48},"100642208","phase-1-a-phase-i-study-of-lipovaxin-tuberculosis-vaccine-in-adult-healthy-populations-100642208","NCT07647107","A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations","A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia","Inclusion Criteria\n\n1. Clinically Healthy participants aged 18-40 years;\n2. Participants have been informed properly regarding the study and signed the informed consent form.\n3. Participants will commit to comply with the instructions of the investigator and the schedule of the trial;\n4. Participants must have a negative IGRA and sputum.\n5. Clinically normal laboratory values for ureum, creatinine, SGOT, SGPT, complete blood count (CBC), urinalysis, coagulation test (PT, aPTT), total cholesterol, Globulin\u002FAlbumin ratio and CRP\n\nExclusion Criteria:\n\n1. Those who are currently diagnosed with tuberculosis or have a history of tuberculosis (positive IGRA or GenXpert sputum test or chest Xray suggestive of TB) and\u002For history of tuberculosis treatment; including TB Preventive Treatment (TPT);\n2. There are serious chronic diseases, or the disease is in the advanced stage that cannot be controlled smoothly, such as diabetes and thyroid disease;\n3. Currently suffering from or within 2 years of any of the following serious diseases, such as: advanced tumor, autoimmune disease, progressive atherosclerosis, acute exacerbation of the chronic obstructive pulmonary disease, acute or progressive liver or kidney disease, congestive heart failure, etc.; based on interview with participants\n4. Those with known or suspected (or high-risk) immune function impairments or abnormalities, such as those receiving more than 20mg\u002Fday of systemic glucocorticoids for 14 consecutive days within the last 4 weeks, immunosuppressants within 3 months, and Those who received protein preparations or blood products or plasma extracts outside the gastrointestinal tract within 3 months;\n5. People with allergic constitution, such as those with a history of allergy to two or more drugs or foods; a history of severe allergy to any component of the test vaccine, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia Purpura, dyspnea, angioedema, etc.; or a history of the above-mentioned serious side effects after using any vaccine or drug in the past; history of bronchial asthma;\n6. Current patients with HIV antibody positive for human immunodeficiency virus;\n7. Women who are pregnant, breastfeeding, or have a positive urine pregnancy test during the screening period, or before vaccination, or who have childbearing plans during the study period;\n8. Subjects receive any vaccination within 1 month before and after dosing;\n9. Those who have participated in any other clinical research and used the investigational drug within 3 months before this clinical research;\n10. Any other situation that the researcher believes may affect the evaluation of the research.",{"count":325,"type":23},60,[327],"PHASE1",[329,330],"Tuberculosis","TB Infection",[332,329,333],"TB vaccine","Lipovaksin TB","2026-06-09",{"date":311,"type":40},{"date":337,"type":23},"2026-08",{"date":339,"type":23},"2027-08",{"name":341,"class":80},"PT Bio Farma",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":57,"minAge":348,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":48},"100641895","heartr-pda-occluder-post-market-follow-up-study-100641895","NCT07646704","HeartR™ PDA Occluder Post-Market Follow-Up Study","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of Patent Ductus Arteriosus (PDA) and were implanted with the HeartR™ PDA Occluder as per IFU instructions\n2. Age ≥ 6 months at the time of implantation.\n3. Weighing ≥ 6 kg at the time of implantation.\n4. Narrowest portion of the PDA ≥ 2mm at the time of implantation.\n\nExclusion Criteria:\n\nPatients did not conduct any follow up visit after hospital discharge.","6 Months",{"count":350,"type":23},140,"The HeartR™ PDA Occluder Post-Market Clinical Follow-up (PMCF) Study is a multi-center, retrospective, single-arm study sponsored by Lifetech Scientific (Shenzhen) Co., Ltd., aiming to evaluate the long-term safety and performance of the Lifetech HeartR™ PDA Occluder in real-world clinical practice in Indonesia. A total of 140 subjects diagnosed with Patent Ductus Arteriosus (PDA) and treated with the HeartR™ PDA Occluder according to the Instructions for Use (IFU) will be enrolled.\n\nEligible subjects include patients aged ≥6 months, weighing ≥6 kg, with a PDA narrowest diameter ≥2 mm at the time of implantation. Patients without any follow-up visit after hospital discharge will be excluded from the study.\n\nThe primary endpoint is procedural success at 12 months post-implantation, defined as the absence of major adverse events including stroke\u002FTIA, device embolization, cardiac or vascular perforation, left pulmonary artery stenosis or aortic stenosis requiring re-intervention, and procedure\u002Fdevice-related death, together with complete defect closure confirmed by Doppler echocardiography without residual shunt.\n\nSecondary endpoints include complete closure rates before discharge and at 6 months post-implantation, incidence of left pulmonary artery stenosis or aortic stenosis requiring re-intervention, incidence of device- or procedure-related adverse events (AEs) and serious adverse events (SAEs), as well as all-cause mortality through 24 months post-implantation.",[353],"Patent Ductus Arteriosus",{"date":311,"type":40},{"date":356,"type":40},"2025-04-30",{"date":130,"type":23},{"name":359,"class":80},"Lifetech Scientific (Shenzhen) Co., Ltd.",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":24,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":382},"100620721","phase-3-a-study-to-test-if-tenecteplase-helps-people-to-recover-from-an-acute-stroke-when-given-more-than-45-hours-after-the-person-was-last-seen-well-100620721","NCT07361302","A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue","TENACITY","Inclusion criteria:\n\n1. Male or female ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n3. Acute ischaemic stroke (including wake-up stroke) affecting the supratentorial circulation (anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral arteries (PCA)) last known well \\>4.5 h before time of presumed randomisation\n4. Pre-stroke modified Rankin scale (mRS) ≤1\n5. Imaging eligibility by magnetic resonance imaging (MRI)computed tomography (CT)\n\nExclusion criteria:\n\n1. Intention to proceed to mechanical thrombectomy (MT) at the same site (hospital) of randomisation\n2. Occlusion of the internal carotid artery (ICA)\n3. High-risk patients (increased risk of thrombolysis related hemorrhage)\n4. Any intracranial hemorrhage detected on non-contrast computed tomography (NCCT) or MRI scans\n5. Contra-indication to contrast brain imaging with CT and MRI\n6. Severe stroke as assessed clinically (National Institute of Health Stroke Scale (NIHSS) \\> 25)\n7. Non-disabling minor stroke symptoms (NIHSS ≤5), or rapidly improving symptoms at the discretion of the investigator\n8. Imaging or clinical findings not indicative of acute ischemic stroke or suggesting stroke older than 72 h\n9. Patients scheduled to receive intravenous (i.v.) thrombolysis as standard of care Further exclusion criteria apply.",{"count":369,"type":23},1325,[146],"This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot.\n\nThe purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already used to treat people within 4.5 hours after they had a stroke. This study tests if tenecteplase also helps if it is given more than 4.5 hours after the stroke.\n\nParticipants are put into 2 groups randomly, which means by chance. One group gets tenecteplase as a single injection into a vein. The other group receives standard medical practice. Participants have an equal chance of receiving tenecteplase or the standard treatment.\n\nParticipants are in the study for about 3 months. In the beginning, participants stay in the hospital for about 1 week. During the study, participants have 7 clinical examinations or visits. The last 2 of these visits will likely be done from home, allowing participants to complete certain assessments remotely. Doctors regularly test participants' recovery using a scale that measures the level of disability or dependence in daily activities. The results are compared between the 2 groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.",[373],"Acute Ischemic Stroke","2026-06-08",{"date":334,"type":40},{"date":377,"type":40},"2026-02-17",{"date":379,"type":23},"2027-10-02",{"name":381,"class":80},"Boehringer Ingelheim",242,{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":18,"sex":19,"minAge":89,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":24,"phases":393,"briefSummary":394,"conditions":395,"keywords":400,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":48},"100643341","effectiveness-and-safety-of-a-hydrating-gel-containing-polyvinyl-pyrrolidine-algin-and-hyaluronic-acid-applied-after-and-without-fractional-co-laser-therapy-100643341","NCT07639151","Effectiveness and Safety of a Hydrating Gel Containing Polyvinyl Pyrrolidine, Algin and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Effectiveness and Safety of a Hydrating Gel Containing Aqua, Carrageenan, Polyvinyl Pyrrolidon, Algin, Gellan Gum, and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Inclusion Criteria:\n\n1. Female participants aged 18-60 years.\n2. Patients attending the Dermatology and Venereology Outpatient Clinic of Universitas Indonesia Hospital (RSUI) who will receive the hydrating gel either following fractional CO₂ laser treatment or without undergoing the fractional CO₂ laser procedure.\n3. Patients who will undergo or have undergone a priming regimen with topical retinoic acid preparations at concentrations of at least 0.025%, 0.05%, or 0.1% for at least 2 weeks prior to fractional CO₂ laser treatment, or prior to study participation in the non-laser group.\n4. Willing to participate in the study and have provided written informed consent after receiving adequate explanation regarding the study.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or currently using oral contraceptives at the time of assessment.\n2. History of systemic retinoid use within the past 3 months.\n3. History of or current treatment for hormonal\u002Fendocrine disorders or other serious medical conditions.\n4. Currently receiving immunosuppressive therapy.\n5. Participants who are unable or unwilling to comply with the study protocol and treatment regimen.","60 Years",{"count":392,"type":23},51,[26],"The purpose of this interventional study is to evaluate the effectiveness and safety of a hydrating gel containing aqua, carrageenan, polyvinyl pyrrolidone, algin, gellan gum, and hyaluronic acid. The study will assess the gel's ability to support optimal skin recovery following fractional CO₂ laser therapy and its effectiveness and safety as a daily adjunctive skincare treatment. Outcomes related to skin hydration, skin barrier function, tolerability, and adverse events will be evaluated throughout the study period.\n\nFemale participants aged 18 to 60 years who provide informed consent will be enrolled in this study. Participants will undergo a 2-week priming period with topical tretinoin prior to fractional CO₂ laser treatment. Clinical evaluations will be performed at baseline, immediately after the laser procedure, and on Days 3, 7, and 14 post-treatment. Assessments conducted by a board-certified dermatologist will include dermoscopy, TEWAmeter assessment, erythema assessment, and evaluation of pain and discomfort using a Visual Analog Scale (VAS).",[396,397,398,399],"Hydration","Carbon-dioxide Laser","Laser Therapy","Hydrogel",[399,401,396],"CO2 Fractional Laser","2026-06-05",{"date":404,"type":40},"2026-06-10",{"date":406,"type":23},"2026-06",{"date":408,"type":23},"2026-09",{"name":410,"class":47},"Dr.dr.Irma Bernadette, SpKK (K)",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":24,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":48},"100605490","smart-bandage-with-telemonitoring-vs-standard-care-for-venous-leg-ulcer-randomized-trial-100605490","NCT07163195","Smart Bandage With Telemonitoring vs Standard Care for Venous Leg Ulcer: Randomized Trial","Smart Bandage With App-Based Telemonitoring vs Standard Care for Venous Leg Ulcer: Randomized Trial","SMART-VLU","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Clinically diagnosed venous leg ulcer persisting for more than 3 weeks\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Age \\>65 years (elderly patients excluded)\n* Acute or emergency wounds\n* Mixed etiology ulcers with significant arterial involvement\n* Severe comorbid illness such as end-stage renal failure or active malignancy\n* Cognitive impairment preventing informed consent\n* Allergy to dressing materials","65 Years",{"count":421,"type":23},110,[26],"Venous leg ulcers (VLUs) are chronic wounds that are often slow to heal and can greatly affect patients' daily lives. This study will evaluate a new \"smart bandage\" that can monitor wound conditions such as pH, temperature, and moisture, and transmit this information to a mobile app for nurses to review. Care can then be adjusted in real time.\n\nThe purpose of this randomized controlled trial is to compare smart bandage plus standard wound care with standard wound care alone. We will assess whether the smart bandage improves healing rates within 12 weeks, shortens time to healing, reduces infection, and improves quality of life in patients with VLUs. About 110 adult participants with VLUs will be enrolled at Clinic Podiatry Care, Purwokerto, Indonesia.",[425,426],"Venous Leg Ulcer (VLU)","Chronic Wound",[428,426,429,430,431,432,433,434,307,435],"Venous Leg Ulcer","Smart Bandage","Telemonitoring","Digital Health","Mobile Application","Wound Care","Wound Healing","Indonesia","2026-06-03",{"date":313,"type":40},{"date":439,"type":23},"2026-07-26",{"date":441,"type":23},"2027-01-27",{"name":443,"class":47},"Asmat Burhan",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":419,"enrollmentInfo":451,"targetDuration":4,"studyType":24,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":48},"100621627","brief-culturally-adapted-behavioral-activation-therapy-for-adults-with-depression-in-indonesian-primary-care-a-type-2-hybrid-effectiveness-implementation-trial-100621627","NCT07373080","Brief Culturally Adapted Behavioral Activation Therapy for Adults With Depression in Indonesian Primary Care: A Type-2 Hybrid Effectiveness-Implementation Trial","Hybrid Type-2 Effectiveness-Implementation Study of Brief Culturally Adapted Behavioral Activation Therapy Delivered by Primary Care Psychologists for Adults With Depression in Indonesian Primary Care Setting: A Study Protocol of Pragmatic Parallel Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* aged 18-65 years old\n* scored 10 or above on PHQ-9\n* provide informed consent\n\nExclusion Criteria:\n\n* having diagnosis of bipolar disorder, psychotic disorders, or substance use disorders",{"count":288,"type":23},[26],"This is a type-2 hybrid effectiveness-implementation study of brief culturally adapted behavioral activation for adults with depression in primary care setting. This clinical trial has two parallel aims: 1) to understand if brief culturally adapted behavioral activation therapy delivered by psychologist in primary care in individual face-to-face session is effective to reduce depressive symptoms among adult patients in Primary Healthcare Centers and 2) to test the outcome of clinical training and supervision on acceptability, feasibility, appropriateness, and fidelity of implementation of brief culturally adapted behavioral activation therapy in Primary Healthcare Centers. The main questions it aims to answer is:\n\n1\\) Is brief culturally adapted behavioral activation intervention delivered by primary care psychologist effective in reducing depressive symptoms among adult patients with depression in primary care settings and 2) Are training and supervision effective in enhancing acceptability, feasibility, appropriateness and fidelity of implementation of brief culturally adapted behavioral activation therapy for adults with depression in primary care settings?",[455],"Depression in Adults",[457,458,459,460,461],"depression","behavioral activation therapy","culturally adapted treatment","implementation science","hybrid trial","2026-05-28",{"date":464,"type":40},"2026-06-01",{"date":466,"type":40},"2026-02-11",{"date":468,"type":23},"2026-07-31",{"name":470,"class":47},"Gadjah Mada University",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":57,"minAge":224,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":481,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":278},"100550374","phase-2-adjunctive-doxycycline-for-central-nervous-system-tuberculosis-100550374","NCT06446245","Adjunctive Doxycycline for Central Nervous System Tuberculosis","DIRECT: Doxycycline Adjunctive Therapy to Reduce Excess Mortality and Complications From Central Nervous System Tuberculosis - Phase II Randomized Clinical Trial","DIRECT","Inclusion Criteria:\n\n1. Aged 21 years and above.\n2. Patients receiving ≤ 7 days of TB treatment or about to start combination TB treatment, including injectable agents, where required.\n3. Patients with clinical evidence of TB meningitis, as per established diagnostic criteria, defined as either definite, probable or possible CNS-TB:\n\n   1. \"Definite\" CNS-TB would be defined if acid-fast bacilli (AFB) or a positive nucleic acid amplification test for M. tuberculosis in the cerebrospinal fluid of patients.\n   2. \"Probable\" CNS-TB would be defined if the patient exhibit one or more of the following: suspected pulmonary tuberculosis on chest radiography, acid-fast bacilli found in any specimen other than the cerebrospinal fluid or clinical evidence of other extrapulmonary tuberculosis.\n   3. \"Possible\" CNS-TB would be defined if the patients exhibit at least four of the following: a history of tuberculosis, predominance of lymphocytes in the cerebrospinal fluid, a duration of illness of more than five days, a ratio of cerebrospinal fluid glucose to plasma glucose of less than 0.5, altered consciousness, yellow cerebrospinal fluid, or focal neurologic signs.\n4. Alanine aminotransferase (ALT) level \\\u003C 3 times the upper limit of normal.\n5. Able to provide informed consent. If the patient has no mental capacity to give consent, then consent may be provided for by the patient's next of kin.\n6. Lumbar puncture and brain imaging (either computed tomography or magnetic resonance imaging, with or without contrast) is required at baseline for enrolment\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnant or breastfeeding\n3. Allergies to tetracyclines\n4. Patients on retinoic acid, neuromuscular blocking agents or pimozide which may increase the risk of drug toxicity.\n5. Autoimmune disease and\u002For on systemic immunosuppressants.\n6. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of the study drug or planned use during the study period.\n7. Enrolment in any other clinical trial involving a systemic drug or intervention involving the CNS.\n8. Contraindications to the use of steroids.\n9. Investigators' assessment of lack of willingness to participate and comply with all requirements including follow-up of the protocol or identification of any factor presumed to significantly increase the participant's risk of suffering an adverse outcome.",{"count":480,"type":23},200,[482],"PHASE2","Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary hospital centers. At present, the SOC for the management of CNS-TB is anti-tuberculous therapy with adjunctive corticosteroids. In CNS-TB, the activity of pathogenic host matrix metalloproteinases (MMPs) is unopposed to tissue inhibitors of metalloproteinases (TIMPs), resulting in a matrix-degrading phenotype which may drive worse outcomes in CNS-TB. In a prior established CNS-TB murine model, the investigators have demonstrated that adjunctive MMP inhibition using doxycycline, a widely available and cheap drug, in addition to standard TB treatment, compared with standard TB treatment alone, improved murine survival (Manuscript in preparation). The investigators previously showed that in humans with pulmonary TB, doxycycline with anti-TB treatment is safe, accelerates the resolution of inflammation, and suppresses systemic and respiratory MMPs. Hence, the investigators are now ideally positioned to determine if adjunctive doxycycline in patients with CNS-TB can improve clinical outcomes. The investigators will perform a Phase 2 double-blind randomized-controlled trial (RCT) of adjunctive doxycycline versus placebo with standard TB treatment and steroids for 8 weeks, with the primary outcome of 8-week mortality or severe neurological deficits.",[485,486,487,488],"Tuberculosis, Meningeal","Tuberculosis; Meningitis (Etiology)","Tuberculosis, Central Nervous System","Tuberculosis; Meningoencephalitis (Etiology)",{"date":464,"type":40},{"date":491,"type":40},"2025-08-21",{"date":493,"type":23},"2027-12",{"name":495,"class":47},"National University Hospital, Singapore",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":57,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":24,"phases":507,"briefSummary":508,"conditions":509,"keywords":513,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":539},"100535583","phase-3-shortened-regimen-for-drug-susceptible-tb-in-children-100535583","NCT06253715","Shortened Regimen for Drug-susceptible TB in Children","SMILE-TB","Inclusion Criteria:\n\n* Parent or guardian is willing and able to provide written informed consent for potential participant's study participation; in addition, when applicable per Ethics Committee\u002FInstitutional Review Board (EC\u002FIRB) policies and procedures, potential participant is willing and able to provide assent for study participation.\n* At Entry, age of less than 10 years.\n* At Entry, weight 3 kilograms (kg) or greater.\n* At Entry, diagnosed with TB disease, defined as:\n\n  * Pulmonary (including pleural effusion) and\u002For lymph node (extra-thoracic and\u002For intra-thoracic) TB with or without bacteriologic confirmation;\n  * Clinician has decided to treat with standard first-line drug-susceptible TB regimen.\n* Known HIV status or HIV testing in progress based on meeting testing requirements.\n* Has normal, Grade 1 or 2 test results for all of the following done at or within 14 days of Entry (including the most recent):\n\n  * Alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal;\n  * Total bilirubin less than or equal to 2.5 times the upper limit of normal;\n  * Potassium level of 3.0 milliequivalent\u002FL or greater;\n  * Hemoglobin level of 7.0 g\u002FdL or greater;\n  * Platelet count of 100,000\u002Fmm3 or greater;\n  * Estimated glomerular filtration rate (eGFR; bedside Schwartz formula) 60 mL\u002Fmin\u002F1.73m2 or higher.\n* For children living with HIV:\n\n  * On antiretroviral therapy (ART) at Entry: Must be on, or able to be switched to a dolutegravir-based regimen at or prior to Entry;\n  * Not on ART at Entry: Planned initiation of dolutegravir before or at study Week 4.\n* For participants who have reached menarche or who are engaging in sexual activity (self-reported): negative serum or urine pregnancy test within 7 days of Entry.\n* For participants who are engaging in sexual activity that could lead to pregnancy (self-reported): agrees to practice at least one non-hormonal method of contraception or abstain from heterosexual intercourse during study drug treatment and for 30 days after stopping study medications. Non-hormonal methods include:\n\n  * Male or female condoms\n  * Diaphragm or cervical cap (with spermicide, if available)\n  * Non-hormonal intrauterine device (IUD) or intrauterine system (IUS)\n* At Entry, intends to remain in the catchment area of the study site for the duration of study follow-up or willingness to be followed up beyond the catchment area if\u002Fwhen applicable, as determined by the site investigator based on participant\u002Fparent\u002Fguardian report.\n\nExclusion Criteria:\n\n* Presumed or documented extra-pulmonary TB involving the central nervous system and\u002For bones and\u002For joints, and\u002For miliary TB, and\u002For pericardial TB and\u002For TB of the gastrointestinal (GI) tract and\u002For renal TB.\n* Premature infant (born less than 37-weeks gestation) who is less than 3 months of age at Entry.\n* Any known contraindication to taking any study drug:\n\n  * Known allergy or intolerance to any of the study drugs or drugs in the same class as the study drugs;\n  * Any prohibited medications within three days prior to Entry or planned use within the following 6 months;\n  * Unable to take oral medications;\n  * Known history of prolonged QT syndrome not caused by electrolyte derangements.\n* Received more than 10 days of treatment directed against TB disease within 6 months preceding initiation of study drugs.\n* M. tuberculosis isolate known or suspected to be resistant to isoniazid, rifampin, pyrazinamide, ethambutol, and\u002For fluoroquinolones.\n* Known exposure to an infectious adult with drug-resistant TB, including resistance to isoniazid, rifampin, pyrazinamide, ethambutol, and\u002For fluoroquinolones.\n* Has any other documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.\n* Previously enrolled in this study.\n\nLate Exclusions:\n\n* M. tuberculosis cultured or detected through World Health Organization (WHO) approved molecular assays (e.g., Cepheid Xpert MTB\u002FRIF, Xpert XDR, sequencing or Hain MTB-DR plus assays) from sputum, swallowed sputum, nasopharyngeal aspirates, stool, or lymph node aspirate obtained around the time of study entry is determined to be resistant to isoniazid and\u002For rifampin and\u002For pyrazinamide and\u002For ethambutol and\u002For fluoroquinolones.\n* Any child with a clinical TB diagnosis who is found to have a definitive alternative diagnosis for their presenting signs and symptoms whose TB treatment is discontinued prior to completion.","0 Days","9 Years",{"count":506,"type":23},860,[146],"While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.",[329,510,511,512],"Tuberculosis, Pulmonary","Tuberculosis, Lymph Node","Mycobacterium Tuberculosis",[514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532],"tuberculosis","pediatric","stratified medicine","shortened regimen","rifapentine","moxifloxacin","dolutegravir","drug-susceptible","lymph node","pulmonary","infections","TB","mycobacterium infections","respiratory tract infections","lung diseases","antitubercular agents","respiratory tract diseases","child","paediatric",{"date":464,"type":40},{"date":535,"type":40},"2025-01-15",{"date":77,"type":23},{"name":538,"class":47},"Johns Hopkins University",9,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":57,"minAge":264,"maxAge":419,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":48},"100630952","effects-of-dual-task-oriented-circuit-training-on-walking-recovery-in-sub-acute-stroke-100630952","NCT07494357","Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke","The Effect of Dual Task-Oriented Circuit Training on Neuroplasticity and Walking Adaptability in Subacute Stroke Patients: A Pilot and Feasibility Study","DTOCT-Stroke","Inclusion Criteria\n\n1. Diagnosed with a first-ever subacute stroke (defined as 2 weeks to 5 months post-onset) with anterior circulation involvement.\n2. Diagnosis confirmed via neuroimaging (CT or MRI).\n3. Men and women aged 40 to 65 years.\n4. Motor recovery in the lower limbs corresponding to Brunnstrom stages 4 to\n5. Functional Ambulation Category (FAC) score of at least grade 3.\n6. Ability to walk independently, with or without walking aids.\n7. Montreal Cognitive Assessment Indonesian version (MoCA-INA) score of ≥20, demonstrating the capacity to collaborate and follow multi-step instructions.\n8. Medically stable with controlled comorbidities.\n\nExclusion Criteria\n\n1. Expressive or receptive aphasia that impedes task comprehension\n2. Unstable cardiovascular or medical conditions (e.g., severe hypertension, congestive heart failure) for which moderate exercise is contraindicated.\n3. Moderate to severe depression, indicated by a Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.",{"count":81,"type":23},[26],"This pilot study aims to assess the feasibility, safety, and initial efficacy of an integrated Dual Task-Oriented Circuit Training (DTOCT) program for individuals in the subacute phase of stroke recovery. Although numerous patients recover the capacity to walk in a regulated hospital environment, they frequently encounter difficulties with \"community ambulation,\" the capability to traverse real-world settings while multitasking (e.g., walking while conversing or circumventing barriers). This study will examine if the integration of high-intensity circuit training with cognitive difficulties can promote neuroplasticity and enhance the patient's capacity to safely traverse intricate daily settings.",[552],"Stroke, Cerebrovascular","2026-05-23",{"date":462,"type":40},{"date":464,"type":23},{"date":557,"type":23},"2026-08-30",{"name":559,"class":47},"Universitas Padjadjaran",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":278},"100606215","phase-2-efficacy-and-safety-study-of-dovramilast-in-people-with-leprosy-type-2-reaction-100606215","NCT07172659","Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction","A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction","Inclusion Criteria:\n\n1. Aged 18 years of age or older.\n2. Provision of written informed consent.\n3. Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.\n4. Leprosy type 2 reaction meeting the following criteria:\n\n   * Either:\n\n     i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).\n   * Presence of at least 10 leprosy type 2 reaction tender papular and\u002For nodular skin lesions (not including scars).\n   * An ENLIST score of at least 9.\n5. If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.\n6. If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.\n\nExclusion Criteria:\n\n1. Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been \\\u003C 28 days.\n2. Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (\\> 50 mg\u002Fday), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive\u002Fimmunomodulatory treatment within 28 days of Baseline.\n3. Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).\n4. Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).\n5. Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.\n6. Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.\n7. Active systemic fungal infection requiring or undergoing treatment.\n8. Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.\n9. Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.\n10. Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.\n11. Pregnant women or breastfeeding mothers.\n12. Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme or use (or planned use) of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem. Substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp should be used with caution when concomitantly administered with dovramilast.\n13. Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.\n14. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.\n15. Current diagnosis of depression, and\u002For history of suicide ideation\n16. History of or presence of cardiac disease, including:\n\n    * Clinically significant abnormal electrocardiogram\n    * QTcF \\> 450 msec\n17. Receipt of a vaccination within 7 days of Baseline.\n18. Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.\n19. Body Mass Index \\\u003C 15 kg\u002Fm\\^2 or \\> 35 kg\u002Fm\\^2.\n20. Unable to, or significant difficulty with, swallowing tablets\u002Fcapsules.\n21. Anemia requiring transfusion.\n22. History of or current pancreatitis.\n23. Known or suspected cirrhosis of the liver.\n24. The following laboratory abnormalities:\n\n    * White blood cells (WBC) \\\u003C 2.5 x 10\\^9\u002F L.\n    * Neutrophils (granulocytes) \\\u003C 1.0 x 10\\^9\u002FL.\n    * Platelets \\\u003C 80 x 10\\^9\u002FL.\n    * Aspartate aminotransferase or alanine aminotransferase \\> 2 times the upper limit of reference range.\n    * Albumin \\\u003C 30 mg\u002FdL.\n    * Bilirubin \\> 2 mg\u002FdL\n    * Calculated creatinine clearance (Cockcroft Gault) \\\u003C 50 milliliter (mL)\u002Fminute.\n    * Lipase ≥ 1.6 times the upper limit\n25. Previous participation in this study\n26. Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments\n27. Enrolled in another leprosy type 2 reaction treatment study",{"count":568,"type":23},45,[482],"Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.",[572],"Erythema Nodosum Leprosum",[574,575],"Leprosy type 2 reaction","dovramilast","2026-05-21",{"date":578,"type":40},"2026-05-26",{"date":580,"type":23},"2026-05-25",{"date":493,"type":23},{"name":583,"class":47},"Medicines Development for Global Health",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":606},"100551953","phase-3-a-phase-3-study-of-efepoetin-alfa-for-treatment-of-anemia-in-patients-with-chronic-kidney-disease-on-dialysis-100551953","NCT06466785","A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","Inclusion Criteria:\n\n1. Adult males and females ≥ 18 years old.\n2. Patient (or patient's legally acceptable representative) has voluntarily signed and dated an informed consent form (ICF), approved by an Ethics Committee (EC) or institutional review board (IRB), after the nature of the study has been explained and the patient has had the opportunity to ask questions.\n3. Patient with stage 5 CKD defined by estimated GFR (eGFR, ≤15 mL\u002Fmin\u002F1.73m2) on adequate HD for a minimum of 12 weeks prior to Day 1. \\*CKD staging will be based on the five-stage system for classification of CKD based on KDIGO guidelines.\n4. Hemodialysis patients with single-pool Kt\u002FV ≥ 1.2 or urea reduction ratio ≥ 65%.\n\n   \\*Single-pool Kt\u002FV or urea reduction ratio will be based on results measured within 4 weeks prior to screening or during the screening period.\n5. Patients must be on stable doses of IV injections of ESA (including biosimilars) for at least 6 weeks prior to Day 1.\n\n   Minimum ESA dose;\n   * Epoetin alfa, epoetin beta, and epoetin kappa: ≥1,500 U\u002Fweek\n   * Darbepoetin alfa: ≥20 µg\u002Fweek\n   * Mircera®: ≥30 µg\u002F2 weeks\n6. Mean of the 2 most recent local laboratory Hb screening values obtained at least 6 days apart, must be 9.0 g\u002FdL to 12.0 g\u002FdL, inclusive, with a difference of ≤1.5 g\u002FdL between the highest and the lowest value.\n7. Patients with serum ferritin ≥100 ng\u002FmL at screening.\n8. Patients with transferrin saturation (TSAT) ≥20% at screening.\n9. Serum folate concentrations ≥lower limit of normal (LLN) at screening.\n10. Serum total vitamin B12 concentrations ≥LLN at screening.\n\nExclusion Criteria:\n\n1. Active acute or chronic infection, or uncontrolled or symptomatic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (e.g., systemic lupus erythematosus, rheumatoid arthritis, celiac disease), or a C reactive protein level 40\\> mg\u002FL (high sensitive C-reactive protein level \\> 10 mg\u002FL).\n2. By history or current clinical evidence, patients with active acute hepatitis B virus (HBV) or hepatitis C virus (HCV) infection should be excluded. Routine screening for HBV, HCV, and human immunodeficiency virus (HIV) infection is not required in this protocol. Chronic HBV\u002FHCV infection with liver function tests (LFT) \\>3 times of normal are excluded. Known HIV positive patients are excluded.\n3. History or clinical evidence of cardiovascular, hematologic, hepatic, or any physical conditions that, in the opinion of the Investigator, would compromise participation in the study.\n4. Any of the following laboratory abnormalities at screening visit;\n\n   * Alanine transaminase (ALT) \\>3 x upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) \\>3 x ULN\n   * Total bilirubin \\>1.5 x ULN\n5. Chronic congestive heart failure (New York Heart Association class III or IV).\n6. High risk for early withdrawal or interruption of the study (due to myocardial infarction, severe or unstable coronary artery disease, stroke, or severe liver disease) within the 12 weeks before Screening or during Screening.\n7. Uncontrolled hypertension defined as a sitting systolic blood pressure ≥170 mmHg and\u002For diastolic blood pressure ≥100 mmHg.\n8. History of active malignancy except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, or in situ cancer at any site.\n9. Patients with a history of overt gastrointestinal bleeding or any other bleeding episode associated with a fall in Hb of ≥1 g\u002FdL within the last 8 weeks prior to Screening.\n10. Known history of myelodysplastic syndrome, multiple myeloma, hereditary hematologic disease such as thalassemia, sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than CKD, hemosiderosis, hemochromatosis, known coagulation disorder, or hypercoagulable condition.\n11. Any prior functioning organ transplant or a scheduled organ transplantation, or anephric state (one or both kidneys).\n12. Planned elective surgery that could lead to significant blood loss during the study period.\n13. Hypoalbuminemia (Serum albumin \\\u003C2.5 g\u002FdL) at Screening Visit.\n14. Androgen, deferoxamine, deferiprone, or deferasirox therapy within 12 weeks prior to Day 1.\n15. Life expectancy of \\\u003C12 months.\n16. Cognitive or psychiatric condition rendering the patient unable to be cooperative with and complete study requirements.\n17. Hypersensitivity to any one of the investigational drugs or its excipients.\n18. Received a blood transfusion (including RBC transfusion) within the 12 weeks prior to Screening, or blood transfusion is anticipated during the study period (excluding temporary blood transfusion given in case of blood loss due to accident or surgery).\n19. Immunosuppressive therapy (tacrolimus\u002Fcyclosporine, and other than corticosteroids for a chronic condition) within 12 weeks prior to Day 1.\n20. History of alcohol or drug abuse within the past 2 years and inability to avoid consumption of more than \\>3 alcoholic beverages per day.\n21. Use of an investigational medication or treatment, participation in an investigational interventional study, or carryover effect of an investigational treatment expected during the study.\n22. Females of childbearing potential or males who are unable\u002Funwilling to take adequate contraceptive precautions defined by the protocol for the duration of the study and for at least 4 months for male subjects and 7 months for female patients after the end of the study. Females with a positive pregnancy test result within 24 hours prior to study entry, are otherwise known to be pregnant, plan to become pregnant in the next 12 months or are currently breastfeeding.\n23. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Sponsor or clinical research organization (CRO) employees directly involved in the conduct of the study.\n24. Patients with very limited functional capacity for which a target Hb value of 12 g\u002FdL may have a lower benefit\u002Frisk ratio.\n25. Any medical condition (patients weighing over 150 kg) that, in the opinion of the Investigator, may pose a safety risk to a patient in this study, may confound efficacy or safety assessment, or may interfere with study participation",{"count":592,"type":23},429,[146],"An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis",[596],"Anemia of Chronic Kidney Disease","2026-05-20",{"date":599,"type":40},"2026-05-22",{"date":601,"type":40},"2024-01-25",{"date":603,"type":23},"2028-03",{"name":605,"class":80},"Genexine, Inc.",58,{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":57,"minAge":89,"maxAge":419,"enrollmentInfo":614,"targetDuration":4,"studyType":24,"phases":615,"briefSummary":616,"conditions":617,"keywords":621,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":48},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232","NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.",{"count":325,"type":23},[146],"The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[618,619,620],"Acute Coronary Syndromes (ACS)","Pneumonia","COPD (Chronic Obstructive Pulmonary Disease)",[622,623,624,625,619,626],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","2026-05-16",{"date":599,"type":40},{"date":630,"type":40},"2026-01-01",{"date":632,"type":23},"2026-10-10",{"name":634,"class":47},"University of Brawijaya",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":57,"minAge":642,"maxAge":89,"enrollmentInfo":643,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":48},"100627689","tb-type-and-spirometry-result-vs-functional-capacity-based-on-6mwt-in-people-with-post-tb-lung-disease-100627689","NCT07451899","TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease","Correlation Between Types of Tuberculosis, Spirometry Result, and Functional Capacity Based on the 6-Minute Walk Test (6MWT) in Adolescents With Post-Tuberculosis Lung Disease.","Inclusion Criteria:\n\n* Adolescents (10-18 year old)\n* Diagnosed with post tuberculosis lung disease by pediatrician\n* Capable of performing the 6MWT\n\nExclusion Criteria:\n\n* Diagnosed with another lung disease\n* Having physical limitations that hinder the 6MWT","10 Years",{"count":644,"type":23},20,"Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent respiratory symptoms, reduced lung volumes, and a threefold higher rate of pulmonary dysfunction compared to healthy children. These conditions could lead to long-term health consequences such as difficulties in performing daily activities. Pulmonary function impairment in PTLD includes approximately 10% of patients losing more than 50% of lung function. Adolescents who have undergone TB treatment often experience pulmonary function impairment and reduced physical capacity. This aims of this study is to analyze the correlation between type of tuberculosis, spirometry result, and functional capacity in adolescents with post-tuberculosis lung disease.\n\nThis study is an analytical observational study with a cross-sectional approach. This study is conducted at Department of Physical Medicine and Rehabilitation, Hasan Sadikin Hospital, Bandung, starting in March until May 2026. Inclusion criteria including: adolescents (10-18 year old), and diagnosed with post tuberculosis lung disease by pediatrician, and capable of performing the 6MWT. The participants with post TB lung disease will undergo spirometry and functional capacity assessment using the 6-minute walk test (6MWT). Outcomes include spirometry result and functional capacity using 6MWT.",[647,648,649,650],"Post Tuberculosis","Lung Disease","Functional Capacity","Spirometry","2026-05-09",{"date":653,"type":40},"2026-05-12",{"date":655,"type":40},"2026-03-01",{"date":657,"type":23},"2026-05-31",{"name":559,"class":47},{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":57,"minAge":264,"maxAge":265,"enrollmentInfo":667,"targetDuration":4,"studyType":24,"phases":669,"briefSummary":670,"conditions":671,"keywords":673,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":680,"completionDateStruct":681,"leadSponsor":683,"locationsCount":48},"100618918","phase-2-phase-iiiii-randomized-trial-of-uc-msc-secretome-vs-sodium-hyaluronate-in-knee-osteoarthritis-100618918","NCT07337863","Phase II\u002FIII Randomized Trial of UC-MSC Secretome vs Sodium Hyaluronate in Knee Osteoarthritis","A Phase II\u002FIII Randomized Double-Blind Multicenter Study Comparing UC-MSC-Derived Secretome and Sodium Hyaluronate on Pain and Function in Patients With Kellgren-Lawrence Grade 2-3 Knee Osteoarthritis","SECRET-OA","Inclusion Criteria:\n\n1. Diagnosed with primary OA in one or both knees based on American College of Rheumatology (Clinical and Rheumatology criteria). If both knees have OA, the knee with the OA grade that falls within the inclusion criteria (grade 2-3) will be selected. If both knees meet the inclusion criteria, the knee with the highest grade and the one that is most uncomfortable will be chosen.\n2. Males or females in the age range 40-70 years\n3. Symptomatic knee OA (defined by pain at the affected joint for at least 3 months before inclusion and visual analog scale 40 - 70 mm on a 100 mm Visual Analog Scale (VAS).\n4. Radiographic evidence of grade 2 to 3 osteoarthritis (OA) based on Kellgren and Lawrence radiographic criteria.\n5. Body mass index between 18 - 30 kg\u002Fm2\n6. Female participants of childbearing age who agreed to use accepted methods of contraception during the course of the study.\n7. Ability to provide written informed consent and willing to participate the study\n\nExclusion Criteria:\n\n1. Participants who, based on physical examination and clinical history (anamnesis), are in the active or acute phase of cardiac, pulmonary, hematological, hepatic, renal, systemic autoimmune, immunodeficiency, or coagulation disorders that may interfere with the administration of the study drug (Secretome or Sodium Hyaluronate) will be excluded,\n2. Diagnosed with a meniscal rupture based on clinical history (anamnesis) and physical examination. If the anamnesis and physical examination show symptoms and signs of a meniscal rupture, further evaluation will be performed using ultrasound (USG),\n3. Participants with significant axial deviation, defined by valgus or varus deformity observed during physical examination, will be excluded,\n4. Participants with other pathological lesions on knee X-rays from the screening examination will also be excluded,\n5. History of any form of secondary arthritis in the knee due to trauma,\n6. History of surgery or major trauma to the knee joint\n7. Has knee effusion,\n8. Has any other inflammatory disorder of the knee joint\n9. Diagnosed with active malignancy.\n10. History of stem cell or secretome therapy.\n11. Intra-articular injection of corticosteroid and\u002For prior treatment with Sodium Hyaluronate and\u002For platelet rich plasma (PRP) in past 3 months.\n12. Use of NSAIDs and\u002For chondroprotective supplements, such as glucosamine and chondroitin sulfate, within 7 days before the trial, whether used orally, topically, or via injection,\n13. Undergoing immunosuppressive therapy, or anticoagulant therapy, or corticosteroid therapy.\n14. For women of child-bearing potential: positive pregnancy test or lactating (females who were planning pregnancy within the next year were excluded).\n15. Enrolled in any other clinical trials within the past four weeks.\n16. The principal investigator considers that the participant is ineligible for the clinical trial due to any reasons other than those listed above",{"count":668,"type":23},50,[482,146],"This study is a randomized, double-blind, multicenter Phase II\u002FIII clinical trial designed to evaluate the effectiveness and safety of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome compared with sodium hyaluronate in patients with knee osteoarthritis. Knee osteoarthritis is a common degenerative joint disease that causes chronic pain and functional limitation. Participants will be randomly assigned to receive intra-articular injections of either UC-MSC-derived secretome or sodium hyaluronate. The study aims to assess improvements in knee pain, physical function, and overall clinical outcomes, as well as to evaluate the safety of the interventions over the study period.",[672],"Knee Osteoarthritis (Knee OA)",[674,675,307,676,677],"Knee Osteoarthritis","UC-MSC Secretome","Sodium Hyaluronate","Intra-articular Injection","2026-05-07",{"date":653,"type":40},{"date":557,"type":23},{"date":682,"type":23},"2027-12-24",{"name":684,"class":47},"Universitas Sriwijaya",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":689,"acronym":690,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":57,"minAge":503,"maxAge":692,"enrollmentInfo":693,"targetDuration":4,"studyType":24,"phases":695,"briefSummary":696,"conditions":697,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":708},"100586886","phase-2-comprehensive-ambulatory-antibiotics-for-the-treatment-of-congenital-syphilis-100586886","NCT06921213","Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis","Cares-1","Inclusion Criteria:\n\n1. Infants at risk of congenital syphilis at birth defined as:\n\n   1. an infant born to a mother who tests positive for syphilis in pregnancy using registered and licensed locally-available diagnostic tests for example but not limited to a Treponemal rapid POCT, an RPR or both.\n\n      AND\n   2. the mother is untreated in the current pregnancy defined as:\n\n   i. she tested positive at antenatal care and received no treatment OR ii. she was never tested during antenatal care OR iii. she tested negative at antenatal care and positive on re-testing at delivery\n\n   OR c. the mother is inadequately treated in the current pregnancy defined as:\n\n   i. Having received a non-penicillin based treatment regimen; and\u002For ii. Does not have documentation of 3 doses of IM Benzathine Penicillin, given 7-10 days apart, with the last dose given \\> 30 days prior to delivery OR b. The mother was adequately treated in the current pregnancy BUT considers herself at risk of re-infection following a midwife delivered explanation of risk (partner treatment, multiple partners etc).\n2. Infants who are asymptomatic for a diagnosis of congenital syphilis following application of a clinical proforma by the study team (Appendix 1)\n3. Infants who are less than \\\u003C= 7 days of life AND with a post-menstrual age (PMA) of 34-42 weeks (Appendix 2).\n4. Infants who are tolerating enteral feeds, including if they are being administered by an NG tube.\n\nExclusion Criteria:\n\n\\- 1. The infant's clinical condition at birth or prior to randomisation requires ongoing (\\> 48 hours) treatment with antibiotics with the potential for anti-treponemal activity i.e. B-lactams, Cephalosporins, Carbapenems.\n\n2\\. They have a birthweight \\\u003C2kg 3. They are nil by mouth. 4. They have a life-limiting congenital anomaly","7 Days",{"count":694,"type":23},90,[482],"CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with \"all-risk\" asymptomatic congenital syphilis.",[698],"Syphilis, Congenital","2026-05-06",{"date":701,"type":40},"2026-05-11",{"date":703,"type":40},"2026-05-04",{"date":705,"type":23},"2027-06-30",{"name":707,"class":47},"London School of Hygiene and Tropical Medicine",3,""]